Bionano Genomics, Inc. Common Stock

BNGO Stock Report Card

Today's performance

37%

Performance

Score:

10/100

BNGO returned -58.19% in the last 12 months. Based on SPY's performance of -7.11%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

Score:

75/100

2 analysts offer 12-month price targets for BNGO. Together, they have an average target of 2.62, the most optimistic target put BNGO at 3.5 within 12-months and the most pessimistic has BNGO at 1.75. These analyst ratings are from our partners at Financial Modeling Prep (https://site.financialmodelingprep.com/) and Alpha Vantage (https://www.alphavantage.co/).

Sentiment

Score:

71/100

BNGO had a bullish sentiment score of 71.15% across Twitter and StockTwits over the last 12 months. It had an average of 334.45 posts, 315.83 comments, and 1,066.99 likes per day.

Technicals

Score:

46/100

BNGO receives a 46 of 100 based on 14 indicators. 6 are bullish, 7 are bearish.

Earnings

Score:

10/100

BNGO has missed earnings 14 times in the last 20 quarters.

Profit

Score:

10/100

Out of the last 20 quarters, BNGO has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

Score:

46/100

BNGO has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

Bionano Genomics, Inc. Common Stock Summary

Nasdaq / BNGO

Healthcare

Diagnostics & Research

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

Pluto is a technology provider that provides you with information, software, and automation tools for the purpose of investment education, but it does not make investment recommendations of securities, investment strategies, or account types, either in general or individualized for you or any other subscriber. If you want to receive individualized investment advice, you should consult with your own financial adviser. Pluto also does not provide you with legal, tax, or accounting advice. You agree that you understand that Pluto is not an investment adviser or a broker-dealer and does not have a fiduciary duty to you or a duty to act in your best interests. Pluto can help you back-test the historical performance of strategies that you create, but it does not recommend strategies and reminds you that the historical performance of a strategy is not a reliable predictor of future results for that strategy. Pluto uses third-party information, for example, about securities market data, that it reasonably believes to be reliable, but it does not warrant that the information is complete, accurate, or up-to-date, and as discussed further below, Pluto does not provide any warranty of merchantability or warranty for a particular purpose for that third-party market data or other information. Investing involves risk, including the risk of loss, and you should not use the Pluto technology in connection with investments unless you are able to and intend to evaluate the technology and the risks and make your own self-directed investment decisions.

Power up your portfolio

Build a portfolio of your favorite stocks

Pluto makes it easy to build investing strategies and automate your portfolio

See how

Checkout Similar Companies

BNGO scored poorly on our reportcard. Here are some similar companies and how they performed.

Merck & Co., Inc.

$MRK Stock Report Card

Johnson & Johnson

$JNJ Stock Report Card

Zomedica Corp.

$ZOM Stock Report Card

Rallybio Corporation Common Stock

$RLYB Stock Report Card

CorMedix Inc.

$CRMD Stock Report Card

Inogen Inc

$INGN Stock Report Card

GENFIT S.A. American Depositary Shares

$GNFT Stock Report Card

Adaptimmune Therapeutics plc American Depositary Shares

$ADAP Stock Report Card

View all stock report cards

Los Angeles, CA

Pluto is not a broker-dealer, investment adviser or member of FINRA. Securities offered by Alpaca Securities LLC (“Alpaca Securities”). Alpaca Securities is a member of FINRA and the Securities Investor Protection Corporation.

Alpaca Securities, LLC (“Alpaca Securities”) is not responsible for and is not providing the technology and services you receive from us to access and manage your brokerage account with Alpaca Securities. You firmly agree to hold Alpaca and its affiliates, owners, directors, employees, clearing firm and agents harmless for any loss or damage arising from the use of or unavailability of the technology and services that we are providing.

The content on this website is for informational purposes only. Pluto does not recommend any specific securities or investment strategies. Investing involves risk & investments may lose value, including the loss of principal. Past performance does not guarantee future results. Investors should consider their investment objectives and risks carefully before investing.